Chemical Properties
Crystalline Solid
Originator
Nycomed Amersham (Norway)
Uses
Cyclooxygenase inhibitor; structurally similar to tenoxicam. Anti-inflammatory; analgesic
Uses
For the treatment of acute mild to moderate pain, as well as pain and inflammation of the joints caused by certain types of rheumatic diseases.
Uses
keratolytic, antiacne, antineoplastic
Uses
Lornoxicam belongs to the oxicam class. It has anti-inflammatory and antipyretic properties. Lornoxicam prevents the synthesis of prostaglandin (PG) by inhibiting cyclo-oxygenase. It is used to relieve various types of symptoms associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute sciatica and low back pain.Lornoxicam is approved for use in Japan.
Lornoxicam has been used as a drug in melanin binding study with cassette dosing and rapid equilibrium dialysis inserts. Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug.
Definition
ChEBI: A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for th
treatment of pain, primarily resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations.
Indications
Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that is used as a painkiller (analgesic). A high level of pain relief is experienced by about 45% of those with moderate to severe postoperative dental pain after a single dose of lornoxicam 8 mg, compared to about 10% with placebo. This is comparable to the proportion experiencing the same level of pain relief with ibuprofen 200 to 400 mg. Adverse events were generally mild and did not differ from placebo in these singe dose studies. There were insufficient data to assess duration of action, but it is likely to be similar to ibuprofen 200 mg.
in vitro
studies on intact human cells showed that lornoxicam intensively inhibit cox-1 and cox-2 with the lowest ic50 among a large panel of nsaids tested. similar findings were obtained in the whole blood for cox-1/-2. in addition lornoxicam suppressed no formation in a dose-dependently manner with an ic50 of 65 μm. [2]
in vivo
in vivo studies found that lornoxicam was as effective as comparative nsaids and that 8 mg lornoxicam was more effective than 10 mg morphine as a pain-reliever after oral surgery. orally administration of lornoxicam at 16-24 mg daily was more effective than tramadol at 300 mg daily in pain-alleviating after knee surgery. compared to naproxen, lornoxicam showed higher therapeutic potency and lower gastrointestinal toxicity. this was probably due to the short half-life of lornoxicam as compared to the other oxicams. [3]
IC 50
a potent cox-1 and cox-2 inhibitor with ic50 values of 5 nm and 8 nm, respectively.
